After over 36 months from the first trametinib administration, and resection of a metastatic lymphadenopathy, the patient experienced complete response.<h4>Conclusions</h4>This case report shows that trametinib could be a valid therapeutic option in patients with metastatic melanoma harboring the rare BRAF K601E mutation. This evidence concerns the gene BRAF and metastatic melanoma.